These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 15996048)
1. Biologic agents and their use in resource-poor countries. Adebajo A; Fursts DE J Rheumatol; 2005 Jul; 32(7):1182-3. PubMed ID: 15996048 [No Abstract] [Full Text] [Related]
2. 50th volume--60 years. A golden year. Scott DG; Moots RJ Rheumatology (Oxford); 2011 Jan; 50(1):1-3. PubMed ID: 21148152 [No Abstract] [Full Text] [Related]
3. Epidemiology of rheumatic musculoskeletal disorders in the developing world. Chopra A; Abdel-Nasser A Best Pract Res Clin Rheumatol; 2008 Aug; 22(4):583-604. PubMed ID: 18783739 [TBL] [Abstract][Full Text] [Related]
4. COPCORD--an unrecognized fountainhead of community rheumatology in developing countries. Chopra A J Rheumatol; 2004 Dec; 31(12):2320-2. PubMed ID: 15570627 [No Abstract] [Full Text] [Related]
5. Leishmaniasis and biologic therapies for rheumatologic diseases. Cascio A; Iaria M; Iaria C Semin Arthritis Rheum; 2010 Dec; 40(3):e3-5. PubMed ID: 19782386 [No Abstract] [Full Text] [Related]
6. The pitfalls in the development of biologic therapy. Maini RN; Feldmann M Nat Clin Pract Rheumatol; 2007 Jan; 3(1):1. PubMed ID: 17202998 [No Abstract] [Full Text] [Related]
8. Conference on epidemiology of rheumatic diseases. Specific needs of developing and developed countries. Santa Ynez, California, November 1-5, 1982. J Rheumatol Suppl; 1983 Nov; 10():1-107. PubMed ID: 6607344 [No Abstract] [Full Text] [Related]
9. MicroRNA in 2012: Biotherapeutic potential of microRNAs in rheumatic diseases. Pers YM; Jorgensen C Nat Rev Rheumatol; 2013 Feb; 9(2):76-8. PubMed ID: 23321608 [TBL] [Abstract][Full Text] [Related]
10. Dawn of the era of biologics in the treatment of the rheumatic diseases. Koopman WJ Arthritis Rheum; 2008 Feb; 58(2 Suppl):S75-8. PubMed ID: 18240221 [No Abstract] [Full Text] [Related]
12. Patterns of rheumatic disease in 11931 Indian patients. Joshi VR J Assoc Physicians India; 1994 Apr; 42(4):346, 348. PubMed ID: 7860574 [No Abstract] [Full Text] [Related]
13. The future of imaging in monitoring biologic therapy. Freeston JE; Emery P Nat Clin Pract Rheumatol; 2007 Jan; 3(1):2-3. PubMed ID: 17202999 [No Abstract] [Full Text] [Related]
14. Methods to analyze real-world databases and registries. Kremers HM Bull NYU Hosp Jt Dis; 2009; 67(2):193-7. PubMed ID: 19583553 [TBL] [Abstract][Full Text] [Related]
15. Registers in the study of pediatric rheumatic diseases--limitations and potential. Gäre BA J Rheumatol; 1996 Nov; 23(11):1834-7. PubMed ID: 8923351 [No Abstract] [Full Text] [Related]
16. [Epidemiologic observations on rheumatic diseases in Croatia (36 months of work with the registry for rheumatic diseases)]. Jajić I; Krapac L Lijec Vjesn; 1984; 106(7-8):318-21. PubMed ID: 6336222 [No Abstract] [Full Text] [Related]
17. Patterns in use and costs of subsidising 5-aminosalicyclic acid compounds and biologic agents in the treatment of inflammatory bowel disease in Australia. Staatz CE; Martin NS; Kong DP; Hollingworth SA Dig Liver Dis; 2018 Mar; 50(3):314-317. PubMed ID: 29311026 [No Abstract] [Full Text] [Related]
18. Mandating coverage of biologic therapies for rheumatic disease: where evidence and politics meet. Bair YA; White RH; Kravitz RL Arthritis Rheum; 2006 Jun; 55(3):353-4. PubMed ID: 16739202 [TBL] [Abstract][Full Text] [Related]